Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Exploratory Trial to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Immunogenicity, and Preliminary Efficacy of WTX221 Infusion in Patients With Refractory Gout

NCT05800041 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT05800041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05800041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Exploratory Trial to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Immunogenicity, and Preliminary Efficacy of WTX221 Infusion in Patients With Refractory Gout
Lead sponsor
RenJi Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
April 10, 2023
Completion date
February 1, 2024
Enrollment
7 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gout tophus